Intensified Regulatory Scrutiny
India's primary drug regulatory body, the Central Drugs Standard Control Organisation (CDSCO), has launched a nationwide campaign to investigate and halt
the unauthorised sale of semaglutide. This initiative targets both physical retail outlets and digital platforms that are reportedly dispensing the medication without requiring valid prescriptions. The CDSCO's directive to its regional and state offices underscores the urgency of ensuring that semaglutide is only accessible through legitimate medical channels, emphasizing that dispensing without a doctor's order poses significant health hazards. This widespread inspection effort is a direct response to growing concerns about the drug's availability to the public without proper medical oversight, aiming to identify and penalize all non-compliant entities. The regulator's focus extends to understanding the entire supply chain to identify how these prescription-only medications are reaching unauthorised sellers, thereby preventing misuse and safeguarding patient well-being, particularly given the drug's high global demand for weight management purposes.
Risks of Unsupervised Use
Semaglutide, known for its effectiveness in managing type 2 diabetes and chronic weight conditions, is a powerful medication that demands strict medical supervision. When used without a doctor's guidance, it can lead to a spectrum of severe adverse effects, including inflammation of the pancreas (pancreatitis), gallbladder complications, kidney dysfunction, and acute allergic reactions. Healthcare professionals consistently highlight the perils of self-medication with semaglutide, stressing that its administration requires careful monitoring for potential side effects and precise dosage adjustments. Experts also point out that individuals may not be aware of the drug's contraindications or its potential interactions with other medications they might be taking. The drug's mechanism involves mimicking incretin hormones to enhance insulin secretion, reduce liver glucose production, and suppress appetite by slowing digestion. While beneficial for specific medical conditions, its indiscriminate use, even by non-medical practitioners like dieticians or gym instructors, presents substantial risks, making adherence to prescription guidelines paramount for patient safety and treatment efficacy.
Regulatory Enforcement and Action
In a significant move, the CDSCO has conducted audits and inspections across 49 entities nationwide, encompassing online pharmacies, warehouses, drug wholesalers, retail stores, and wellness clinics. This comprehensive surveillance aims to identify violations related to unauthorised sales, improper prescription practices, and misleading marketing of semaglutide. Following these inspections, notices have been issued to all entities found to be non-compliant with drug sale regulations. The drug regulator has reiterated its stance that semaglutide is approved for use in India strictly under the prescription of endocrinologists, internal medicine specialists, and for certain indications, cardiologists. Any promotional activity that encourages public demand for the drug, exaggerates its benefits, or downplays the importance of lifestyle changes is being strictly monitored and will be considered misleading promotion. The regulatory body has warned that non-compliance will be met with severe penalties, including the cancellation of licenses, imposition of fines, and legal prosecution under applicable laws. The CDSCO has also urged the public to report any instances of unauthorised sales to their local drug control offices, assuring swift action against offenders.
